Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

50.51 +0.67 (+1.34%)
Streaming Delayed Price Updated: 10:12 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
37 38 Next >
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. 
Via Benzinga
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Analyzing NASDAQ:SNY's Dividend Potential.
Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY). 
Via Chartmill
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
Via Investor's Business Daily
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... 
Via Benzinga
Why NASDAQ:SNY is a Top Pick for Dividend Investors.
Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential. 
Via Chartmill
Looking Into Sanofi's Recent Short Interest
 
Via Benzinga
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals.
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. 
Via Benzinga
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. 
Via Benzinga
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger... 
Via Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year 
Via Talk Markets
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD 
Via Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
SANOFI-ADR (NASDAQ:SNY): good value for what you're paying. 
Via Chartmill
Why First Wave BioPharma Shares Are Skyrocketing Today
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of  
Via Benzinga
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan 
Via Benzinga
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr 
Via Benzinga
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... 
Via Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
You can pick these players up for a great price right now. 
Via The Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium  
Via Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)  
Via Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus 
Via Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.